Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-06-02 | Genovis | Genovis AB: Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Genovis AB: Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science MarketsThe newly developed IgM-specific protease demonstrates a remarkable level of effectiveness, exhibiting exceptional specificity towards IgM antibodies, which play a critical role in the early stages of immune response. These characteristics positions the enzyme as a valuable tool for cutting-edge research and diagnostic applications, providing researchers and diagnostic professionals with enhanced precision and accuracy in their investigations. Moreover, data strongly suggest that the prevalence of neutralizing antibodies targeting the IgM protease among the human population is very low. This finding paves the way for potential therapeutic uses of the enzyme in diverse areas, including the treatment of cancer and autoimmune diseases. The enzyme’s specific targeting of IgM presents an exciting opportunity to explore novel therapeutic strategies and open new possibilities for advancing the development of innovative treatments. ”The launch of our unique IgM-specific protease, IgMBRAZOR™, represents an important milestone in our strategy to expand our unique antibody digestion platform and position Genovis as the leading company in immunoglobulin cleaving enzymes,” said Fredrik Olsson, CEO of Genovis. ”With its remarkable efficiency, specificity, and potential therapeutic applications, we believe this innovative enzyme will make notable contributions to research, diagnostics, and the potential treatment of various diseases.” As part of its commitment to advancing life science research and supporting the healthcare community, Genovis plans to collaborate with leading academic institutions, research organizations, and industry partners to explore the full scope of the IgM-specific protease’s applications. For more information about Genovis’s IgM-specific protease, please visit: https://www.genovis.com/smartenzymes/antibody-digestion/igmbrazor/ |
||||
2023-06-02 | Genovis | Genovis AB: Genovis lanserar unikt IgM-specifikt enzym med breda tillämpningar inom Life Science-marknaden | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Redeye | Redeye: Genovis Q1 2023 - Strongest report to date | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Kommuniké från Årsstämman i Genovis AB (publ) den 16 maj 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Genovis AB: Interim Report January-March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Genovis | Genovis AB: Kvartalsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Genovis | Genovis AB: Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Genovis | Genovis AB: Genovis och ArcticZymes Technologies ingår samarbetsavtal för att accelerera tillväxt på den kinesiska marknaden | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis acquires IP Rights to novel enzymes for applications within genomics | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis förvärvar patenträttigheter till nytt enzym inom genomics | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis årsredovisning 2022 publicerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-25 | Genovis | Genovis AB: Genovis Annual Report 2022 published | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-11 | Genovis | Genovis AB: NOTICE CONVENING THE 2023 ANNUAL GENERAL MEETING | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-11 | Genovis | Genovis AB: KALLELSE TILL ÅRSSTÄMMA 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-16 | Redeye | Redeye: Genovis Q4 2022 - A First Sublicensing of Xork | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Genovis | Genovis AB: Year-end Report January-December 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Genovis | Genovis AB: Bokslutskommuniké januari-december 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-01-09 | Genovis | Genovis AB: Genovis erhåller direkt 4 MUSD efter att Selecta Biosciences sub-licensierat Xork™-enzymet till Astellas Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-09 | Genovis | Genovis AB: Genovis to receive 4 MUSD upfront after Selecta Biosciences sublicensed Xork™ enzyme to Astellas Pharma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-12-12 | Redeye | Redeye: Genovis - Bull Story, Fair Price | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-15 | Genovis | Genovis AB: Interim Report January-September 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2022-11-15 | Genovis | Genovis AB: Delårsrapport januari-september 2022 | Rapporter | Ladda ner | Visa Stäng |
|